Clinical Trials Browser

Phase 2 × INDUSTRY × andecaliximab × Clear all

NCT02862574 2018-06-27

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Phase 2 Terminated

15 enrolled 11 charts

Arthritis, Rheumatoid